Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases

Area of Science:

• Pharmacology
• Nephrology
• Drug Metabolism

Background:

• Chronic Kidney Disease (CKD) is a growing global health concern.
• CKD significantly impairs non-renal drug clearance mechanisms, including metabolic enzymes and transporters.
• Accumulated uremic toxins in CKD can alter the expression and activity of these drug-metabolizing systems.

Purpose of the Study:

• To review the impact of CKD on non-renal drug clearance.
• To examine the role of metabolic enzymes and transport pathways in drug disposition during CKD.
• To provide insights into drug metabolism and distribution alterations in CKD patients.

Main Methods:

• Literature review focusing on animal experiments and clinical investigations.
• Analysis of studies investigating drug metabolic enzymes and transporters in CKD.
• Synthesis of data on non-renal drug clearance in renal failure.

Main Results:

• Non-renal drug clearance is significantly affected in CKD.
• Metabolic enzyme systems and transport pathways are dysregulated in both animal models and human patients with renal failure.
• Uremic toxins contribute to the downregulation or inhibition of drug-metabolizing enzymes and transporters.

Conclusions:

• Alterations in drug metabolic enzymes and transporters in the kidney, liver, and intestine are crucial to pharmacokinetic changes in CKD.
• The metabolism and transportation of medications used in CKD patients are likely impacted by these alterations.
• Understanding these changes is vital for appropriate drug dosing and therapeutic outcomes in CKD management.